lilly retatrutide Retatrutide: The New Triple-Agonist Weight Loss Treatment eli lilly retatrutide trial sign

Cardiovascular & Renal Benefits of GLP-1 Receptor Agonists Meta-analysis (2024) comprehensive review showing GLP-1RAs reduce major adverse cardiovascular events (MACE), all-cause mortality, stroke, and kidney-related outcomes, in patients with and without diabetes

A.TrentiT.et al (2011)

However, there exist other cAMP mediators, namely Epac [91,92] and other pathways like the inositol 1,4,5-trisphosphate (IP3), that also could be involved in the GLP-1 action [89,92,93,94]

These trials were specifically monitored for cancer-related adverse effects and found no notable differences in thyroid cancer incidence between the treatment and control groups

Importantly, GLP-2R is not expressed on enterocytes